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Background: Antimicrobial resistance (AMR) is a critical health problem, with systemic antimicrobial therapy
driving development of AMR across the host spectrum.
Objectives: This study compares longitudinal carriage, at multiple timepoints, of AMR faecal Escherichia coli in
dogs undergoing routine antimicrobial treatment.
Methods: Faecal samples (n"457) from dogs (n"127) were examined pretreatment, immediately after treat-
ment and 1 month and 3 months post-treatment with one of five antimicrobials. Isolates were tested for sus-
ceptibility to a range of antimicrobials using disc diffusion for each treatment group at different timepoints; the
presence/absence of corresponding resistance genes was investigated using PCR assays. The impact of treat-
ment group/timepoint and other risk factors on the presence of resistance [MDR, fluoroquinolone resistance,
third-generation cephalosporin resistance (3GCR) and ESBL and AmpC production] was investigated using multi-
level modelling. Samples with at least one AMR E. coli from selective/non-selective agar were classed as positive.
Resistance was also assessed at the isolate level, determining the abundance of AMR from non-selective culture.
Results: Treatment with b-lactams or fluoroquinolones was significantly associated with the detection of 3GCR,
AmpC-producing, MDR and/or fluoroquinolone-resistant E. coli, but not ESBL-producing E. coli, immediately after
treatment. However, 1 month post-treatment, only amoxicillin/clavulanate was significantly associated with the
detection of 3GCR; there was no significant difference at 3 months post-treatment for any antimicrobial com-
pared with pretreatment samples.
Conclusions: Our findings demonstrated that b-lactam and fluoroquinolone antibiotic usage is associated with
increased detection of important phenotypic and genotypic AMR faecal E. coli following routine therapy in vet-
visiting dogs. This has important implications for veterinary and public health in terms of antimicrobial prescrib-
ing and biosecurity protocols, and dog waste disposal.
Introduction
The gastrointestinal tract is an important reservoir for
antimicrobial-resistant (AMR) Gram-negative organisms.1,2 MDR
(resistance to three or more antimicrobial classes),3 ESBL- and
AmpC-producing faecal Escherichia coli carried by dogs are of par-
ticular concern. They may act as a reservoir for self-infection,
which may lead to further transmission of resistance genes, as
well as pathogens and resistance genes potentially being
transferred into other hosts, including people, other pets and the
environment.4–6 Systemic antimicrobial therapy selects for AMR
Gram-negative bacteria, so increased use compounds AMR issues.
In humans, even short-term therapy with ciprofloxacin, a cephalo-
sporin or clindamycin can lead to long-term disturbance of com-
mensal bacterial populations and prolonged carriage of AMR
Enterobacteriaceae or anaerobic bacteria.7,8
There are a limited number of (mostly broad-spectrum) antimi-
crobials authorized for use in companion animals in the UK.
Amongst these, b-lactams and fluoroquinolones are commonly
utilized and critically important for the treatment of bacterial infec-
tions.9 b-Lactam antimicrobials include oral cefalexin, oral
amoxicillin/clavulanate, the most commonly prescribed, for dogs,
by first-opinion veterinarians,10,11 and injectable cefovecin
(administered subcutaneously every 14 days). Enrofloxacin and
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marbofloxacin are oral second-generation fluoroquinolones and
clindamycin is an oral lincosamide antimicrobial.7,12
The overall effect of antimicrobial treatment on human com-
mensal bacterial populations has been shown to depend on the
pharmacokinetics, spectrum of activity, dose and treatment dur-
ation, and the levels of AMR bacteria present before treatment.7 In
dogs, a number of studies have shown that treatment with either
b-lactam or fluoroquinolone antimicrobials may positively select
for intestinal/faecal AMR E. coli for variable periods of time.13–20
This study aimed to compare the extent and characteristics of
AMR E. coli carriage in the faeces of community dogs before and
after treatment with five different antimicrobials.
Materials and methods
Study population
Dogs attending veterinary consultations at three centres, including first-
opinion and referral practice, in the North-West of England between June
2011 and September 2012 were recruited. Inclusion criteria were dogs
diagnosed with a bacterial infection (skin, soft tissue, urinary tract, dental,
respiratory tract, orthopaedic, gastrointestinal, ocular) requiring systemic
antimicrobial therapy with one of five antimicrobials authorized for use,
including cefalexin, amoxicillin/clavulanate, cefovecin, clindamycin or a
fluoroquinolone (enrofloxacin or marbofloxacin). Exclusion criteria included
antimicrobial therapy or veterinary admission within the previous 3 months
and dogs aged ,12 months (due to fluoroquinolone contraindication).
Dogs were excluded if they were prescribed systemic antimicrobials during
the follow-up period. The veterinarian in charge of the case selected
and implemented the treatment plan (antimicrobial, dose, frequency and
duration) according to clinical need. Before enrolment, all dog owners read
the study outline and gave written informed consent. The University’s
Veterinary Science Ethics Committee approved the study protocol in
June 2011.
Detection and characterization of faecal E. coli
E. coli isolation
Owners were asked to provide a fresh faecal sample from their dog pre-
treatment, immediately after treatment and at 1 month and 3 months
post-treatment. Samples were delivered in person or by first-class pre-paid
return post. Faecal samples were refrigerated and processed on delivery
(within 24–72 h of collection).
All faecal samples were processed by selective and non-selective meth-
ods, as previously reported.21–24 In brief, equal volumes of faeces (5 g) and
brain heart infusion broth with 5% glycerol (BHI-G) (5 mL) were homogen-
ized before streaking onto plain eosin methylene blue agar (EMBA), EMBA
impregnated with third-generation cephalosporins (1lg/mL ceftazidime
and 1lg/mL cefotaxime) and spread-plating onto plain EMBA with anti-
microbial discs (10lg ampicillin, 30lg amoxicillin/clavulanate, 1lg cipro-
floxacin, 30lg chloramphenicol, 30lg nalidixic acid, 30lg tetracycline and
2.5lg trimethoprim).22 Following overnight aerobic incubation at 37C,
when present, 10 random colonies, morphologically resembling E. coli,
were selected from plain EMBA and one colony from each (ceftazidime/
cefotaxime) impregnated EMBA plate and/or growing within the inhibition
zone around each antimicrobial disc was selected for further investigation;
this methodology was used to investigate whether there is a reduction in
diversity and/or emergence of low-prevalence AMR clones following anti-
microbial selective pressure.4,22,25 It was therefore possible to select a max-
imum of 19 isolates from each faecal sample. Selected colonies were
sub-cultured onto nutrient agar for pure growth and incubated aerobically
overnight at 37C before Gram staining, biochemical analysis (catalase pro-
duction, lack of oxidase, lactose fermentation, indole production and
inability to use citrate as a carbon source). PCR assays for the uidA gene26
confirmed isolates as E. coli. All antimicrobial discs were obtained from
MAST Group Ltd, Liverpool, UK, and media from LabM Ltd, Bury, UK; ceph-
alosporin powder was from Sigma–Aldrich Company Ltd, Gillingham, UK.
Antimicrobial susceptibility testing
All confirmed E. coli isolates underwent antimicrobial susceptibility disc-
diffusion testing and interpretation as previously reported24 according
to BSAC guidelines27 with the same panel of seven antimicrobial discs as
used above. E. coli ATCCV
R
25922 (LGC Standards, Teddington, UK) cultured
overnight on nutrient agar at 37C was the control.
ESBL- and AmpC-producing E. coli
Isolates selected from third-generation-cephalosporin-impregnated EMBA
and isolates from other selective and non-selective agar with phenotypic
resistance to ampicillin or amoxicillin/clavulanate were further screened for
third-generation cephalosporin resistance (3GCR) (10lg of cefpodoxime )
and phenotypic ESBL and AmpC production, according to the manufac-
turer’s instructions (Extended Spectrum b-Lactamase Set D52C, MAST
Group Ltd, Liverpool, UK, and AmpC detection set D69C, MAST Group,
Liverpool, UK).28,29 E. coliATCCV
R
25922 (LGC Standards, Teddington, UK) cul-
tured overnight on nutrient agar at 37C was the control. Isolates with
phenotypic ESBL or AmpC production were further tested for the presence
of blaCTX-M,
30 blaSHV, blaTEM and blaOXA genes,
31 and blaAmpC genes,
32 includ-
ing blaCIT-M as a screen for blaCMY (the most common AmpC gene in the
UK).24,33 If positive for blaCTX-M, isolates were tested for the presence of CTX-
M group-1, -2 and -9 genes,34,35 as these are reported to be the most com-
mon CTX-M-group genes amongst animals in the UK.24,36
Statistical analyses
Sample-level prevalence of AMR over time
All isolates (from selective and non-selective agar) were included in the
analysis. To account for multiple isolates per sample, microbiological data
were collapsed to sample level, such that a sample with at least one resist-
ant isolate was classed as resistant. Five resistance outcomes were consid-
ered: fluoroquinolone resistance (FQR), 3GCR, phenotypic ESBL or AmpC
producing and MDR. The percentages of samples with each of the five re-
sistance outcomes were calculated (including 95% CIs) for each treatment
group/timepoint.
Isolate-level prevalence of AMR over time
To quantify the abundance of AMR E. coli for each treatment group/time-
point, 10 random isolates (if available) from non-selective EMBA were
tested from each sample (n"3897 isolates). The percentage of isolates
(including 95% CIs) with resistance to each tested antimicrobial or MDR
was determined for each treatment group/timepoint.
Risk factors for AMR faecal E. coli
Questionnaire data. A questionnaire investigating potential risk fac-
tors for AMR bacteria was completed by owners at the start of the study
and at each faecal collection. The attending veterinary surgeon completed
a one-page questionnaire detailing diagnosis, treatment regimen and pre-
vious antimicrobial treatment within the last 12 months. All questionnaire-
derived information was available as potential explanatory variables for
inclusion in multivariable modelling of AMR outcomes. Except for age, all
variables were categorical. Collinearity between explanatory variables was
assessed using two-by-two tables and Pearson’s v2 test for independence
or Fisher’s exact tests if N,5. A one-way between-groups analysis of vari-
ance (ANOVA) was used to investigate differences between animals of
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different ages (normal distribution) within treatment groups pretreatment
(Table 1). To investigate significant pretreatment differences between
treatment groups, for each AMR outcome (FQR, 3GCR, MDR and ESBL- and
AmpC-producing E. coli) and questionnaire-derived variables, simple uni-
variable and multivariable logistic regression analysis with a binomial distri-
bution and logit link function were used. All questionnaire data analyses
were undertaken using the SPSS software package (SPSS 20.0 for Mac, SPSS
Inc., Chicago, IL, USA).
Multilevel models. Multilevel multivariable logistic regression model-
ling was used to examine differences between treatment groups/time-
points, including dog as a random-effect term (level-2 unit, due to repeated
measurements in dogs). Faecal samples were the level-1 unit of interest. At
enrolment all dogs were classed as ‘untreated’. The different combinations
of time (n"3) and treatment group (n"5) provided 15 categories for
analyses.
Univariable analyses were initially performed; all variables showing
some association with the resistance outcome (P,0.25)37 were considered
for incorporation in the final multivariable model. Models were constructed
using backwards stepwise procedures where variables with a Wald P value
,0.05 were retained; treatment group/timepoint were always retained.
Once a final multivariable model was generated, all variables significantly
(P,0.05) different between treatment groups at baseline were forced into
the multilevel model to ensure that there was no confounding effect on
remaining variables.
Univariable and multivariable calculations utilizing penalized quasi-
likelihood estimates [second-order predictive quasi-likelihood (PQL) for
all outcomes other than phenotypic ESBL, which was first-order marginal
quasi-likelihood (MQL) due to lack of model convergence]38 were per-
formed. First-order interaction terms were tested for all variables remain-
ing in final models. The residuals+1.96 SD% rank (caterpillar plots) were
calculated and graphed for each dog to check for outliers. Multilevel
models were analysed using the MLwiN statistical software package
(MLwiN Version 2.28 Centre for Multilevel Modelling, University of Bristol).
Results
Study population
One hundred and twenty-seven dogs were enrolled from three
centres (Table S1, available as Supplementary data at JAC Online).
All dogs provided samples pretreatment and at treatment end,
Table 1. Pretreatment variables considered for inclusion in the final multivariable model, with the number and percentage of dogs in each treatment
group and variable category
Variable
Cefalexin
(n"32)
Amoxicillin/clavulanate
(n"28)
Cefovecin
(n"24)
Clindamycin
(n"29)
Fluoroquinolone
(n"14)
Total
(n"127) P
Mean agea (months) 44 50 68 79 83 62 0.002
Weight 0.002
small (,11 kg) 1 (5) 2 (10) 3 (15) 10 (50) 4 (20) 20 (16)
medium (11–20 kg) 4 (25) 3 (19) 0 7 (44) 2 (13) 16 (13)
large (.20 kg) (ref.) 27 (30) 23 (25) 21 (23) 12 (13) 8 (9) 91 (72)
Gender 0.8
male (ref.) 19 (25) 17 (23) 12 (16) 17 (23) 10 (13) 75 (59)
female 13 (25) 11 (21) 12 (23) 12 (23) 4 (8) 52 (41)
Treatment duration 0.001
1 week (ref.) 6 (18) 16 (47) 0 10 (29) 2 (6) 34 (27)
.1 to ,3 weeks 12 (26) 9 (19) 9 (19) 11 (23) 6 (13) 47 (37)
.3 weeks 14 (30) 3 (7) 15 (33) 8 (17) 6 (13) 46 (36)
Recruitment site 0.001
first-opinion practice (ref.) 24 (33) 27 (37) 4 (5) 17 (23) 1 (1) 73 (57)
referral consultation 8 (15) 1 (2) 20 (37) 12 (22) 13 (24) 54 (43)
Diagnosis of pyoderma at enrolmentb 28 (35) 3 (4) 23 (28) 16 (20) 11 (14) 81 (64) 0.001
Previous systemic antimicrobial treatmentc 16 (26) 10 (16) 17 (28) 10 (16) 8 (13) 61 (48) 0.048
Previous b-lactam antimicrobial treatmentc 11 (28) 7 (18) 9 (23) 7 (18) 6 (15) 40 (31) 0.41
Previous hospital admissionc 17 (42) 12 (29) 5 (12) 6 (15) 1 (2) 41 (32) 0.007
In-contact human or pet received antimicrobialsd 7 (26) 5 (19) 4 (15) 7 (26) 4 (15) 27 (21) 0.9
In-contact human or pet admitted to hospital or
veterinary premisesd
4 (15) 3 (12) 6 (23) 8 (31) 5 (19) 26 (20) 0.2
Owner works in healthcare 5 (21) 2 (8) 4 (17) 10 (42) 3 (13) 24 (19) 0.08
Multi-dog household 18 (32) 15 (26) 12 (21) 8 (14) 4 (7) 57 (45) 0.1
Enrolled dog regularly eats animal stools 7 (18) 5 (13) 8 (21) 11 (29) 7 (18) 38 (30) 0.08
ref., reference category for non-dichotomous variables.
Significant if P,0.05 (bold text) (Pearson’s v2 or aANOVA).
aAge was the only continuous value and is represented by the mean age of dogs in each treatment group.
bOther infections (n"46) include urinary tract/prostate (n"11), abscess/bite wound (n"11), dental (n"10) and post-operative (n"8).
cWithin 12 months, but .3 months, as per enrolment criteria.
dWithin 12 months of enrolment.
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105 dogs provided samples at 1 month post-treatment and 98
dogs provided samples at 3 months post-treatment. Information
regarding sample timepoints and the reasons for missing samples
are described in the Supplementary data available at JACOnline.
Detection and characterization of faecal E. coli
E. coli was detected in 95% (434/457) of faecal samples. 3GCR was
detected in 158 samples from 60% of dogs, phenotypic ESBL-
producing E. coli were detected in 59 samples from 31% of dogs
and AmpC-producing E. coli were detected in 138 samples from
60% of dogs (Table S2). Table 2 shows the number and percent-
age of samples with at least one faecal E. coli with ESBL- and/or
AmpC-producing genes for each timepoint/treatment group.
Carriage of blaCIT-M was detected in the faecal samples of 50% of
dogs during the full study period; blaDHA-1/blaDHA-2 and blaMOX were
detected from only one dog each in addition to blaCIT-M. The most
commonly detected blaCTX-M genes belonged to group 1 (13% of
dogs) followed by group 9 (2% dogs); blaCTX-M group-2 genes were
detected in E. coli from a single dog at 1 month post-
fluoroquinolone treatment.
Sample-level prevalence of AMR
Generally there was an increased percentage of samples with
MDR, ESBL- or AmpC-producing E. coli following treatment with
cefalexin, amoxicillin/clavulanate and cefovecin and an increased
percentage of samples with FQR E. coli following cefalexin, cefove-
cin and fluoroquinolone treatment. However, the percentage of
samples with resistance had generally declined by 3 months post-
treatment (Figure 1).
Prevalence of AMR at the isolate level
During the full study period, isolates (n"3897: pretreatment
n"1097, immediately post-treatment n"1011, 1 month post-
treatment n"911 and 3 months post-treatment n"878) were
randomly selected from non-selective agar. For all treatment
groups, the percentage of isolates with resistance to each tested
antimicrobial and MDR increased immediately post-treatment
compared with pretreatment, but declined by 3 months post-
treatment (Figure 2); of note was the increased detection of MDR
and a lack of fully susceptible isolates immediately after fluoro-
quinolone treatment (Figure 2).
Table 2. Number (percentage) of samples that harboured at least one faecal E. coli positive for ESBL or AmpC resistance genes for each timepoint/
treatment group
Treatment group
Timepoint and
total samples blaCTX-M
CTX-M
group 1
CTX-M
group 9 blaCIT-M
blaCTX-M and
blaCIT-M
Phenotypic ESBL
with blaTEM and/or blaOXA
a
Cefalexin D0 (n"32) 1 (3) 1 (3) 0 4 (13) 0 0
E (n"32) 4 (13) 3 (9) 0 19 (60) 4 (13) 1 (3)
M1 (n"27) 2 (7) 2 (7) 0 9 (33) 0 1 (4)
M3 (n"24) 0 0 0 4 (17) 0 0
Amoxicillin/clavulanate D0 (n"28) 0 0 0 5 (18) 0 0
E (n"28) 1 (4) 1 (4) 0 9 (32) 0 1 (4)
M1 (n"26) 1 (4) 1 (4) 0 7 (27) 0 1 (4)
M3 (n"25) 1 (4) 0 1 (4) 5 (20) 0 0
Cefovecin D0 (n"24) 5 (21) 5 (21) 0 9 (38) 3 (13) 1 (4)
E (n"24) 6 (25) 4 (17) 1 (4) 15 (63) 4 (17) 1 (4)
M1 (n"19) 5 (26) 2 (11) 2 (11) 5 (26) 3 (16) 1 (5)
M3 (n"18) 1 (6) 1 (6) 0 7 (39) 2 (11) 1 (6)
Clindamycin D0 (n"29) 0 0 0 5 (17) 0 1 (4)
E (n"29) 1 (3) 0 0 3 (10) 0 1 (4)
M1 (n"25) 1 (4) 1 (4) 0 2 (8) 0 0
M3 (n"23) 0 0 0 1 (4) 0 0
Fluoroquinolone D0 (n"14) 2 (14) 2 (14) 0 4 (29) 1 (7) 1 (7)
E (n"14) 3 (21) 2 (14) 0 3 (21) 2 (14) 1 (7)
M1 (n"7) 1 (14) 1 (14) 0 1 (14) 0 0
M3 (n"8) 1 (13) 1 (13) 0 2 (25) 1 (13) 0
Treatment overall D0 (n"127) 8 (6) 8 (6) 0 27 (21) 4 (3) 3 (2)
E (n"127) 14 (11) 10 (8) 1 (1) 49 (39) 10 (8) 5 (4)
M1 (n"105) 9 (9) 7 (7) 2 (2) 24 (23) 3 (3) 4 (4)
M3 (n"98) 3 (3) 2 (2) 1 (1) 19 (19) 3 (3) 1 (1)
Total dogs, n"127 22 (17) 16 (13) 3 (2) 63 (50) 13 (10) 13 (10)
Treatment overall, all antibiotics; Total dogs, dogs with ESBL or AmpC genes during the full study period (a dog was classed as positive if at least one
isolate in one sample was positive); D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment.
aSequencing was not performed to confirm carriage of genes blaTEM and blaOXA.
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Risk factors for AMR faecal E. coli
When compared with all pretreatment samples, MDR E. coli was
significantly more likely to be detected following treatment with
amoxicillin/clavulanate or cefovecin (Table 3). The risk of detecting
3GCR E. coli was higher following treatment with amoxicillin/
clavulanate, cefalexin or cefovecin; for AmpC-producing E. coli,
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Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and Amp-C-producing (d) E. coli at each
timepoint for each treatment group and treatment overall (95% CI). D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months
post-treatment; LEX, cefalexin; AMC, amoxicillin/clavulanate; CVN, cefovecin; CLI, clindamycin; FQ, fluoroquinolone.
Antibiotics select for AMR canine faecal E. coli JAC
3309
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/12/3305/5095201 by U
niversity of Liverpool user on 23 January 2019
010
20
30
40
50
60
70
80
90
100
(a)
(b)
(c)
All D0
All E
All M1
All M3
0
10
20
30
40
50
60
70
80
90
100
AC D0
AC E
AC M1
AC M3
0
10
20
30
40
50
60
70
80
90
100
AMP AMC CIP CHL NAL TET TMP MDR Susc.
AMP AMC CIP CHL NAL TET TMP MDR Susc.
AMP AMC CIP CHL NAL TET TMP MDR Susc.
LEX D0
LEX E
LEX M1
LEX M3
Figure 2. Percentage of isolates with resistance or susceptibility in each treatment group [overall treatment (a), amoxicillin/clavulanate treatment
(b), cefalexin treatment (c), cefovecin treatment (d), clindamycin treatment (e) and fluoroquinolone treatment (f)] at each timepoint (95% CI). AMP,
ampicillin; AMC, amoxicillin/clavulanate; CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; TET, tetracycline; TMP, trimethoprim; Susc., fully
susceptible; All, all treatment groups; D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; LEX, cefalexin;
CVN, cefovecin; CLI, clindamycin; FQ, fluoroquinolone.
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cefalexin or cefovecin therapies increased the risk of detection
(Table 4). Finally, fluoroquinolone-resistant E. coli was more likely
to be detected following treatment with cefalexin, a fluoroquino-
lone or cefovecin (Table 3). At 1 month post-amoxicillin/
clavulanate, the risk of detecting 3GCR E. coli increased compared
with pretreatment samples (Table 4); no other significant differen-
ces were detected at 1 month or 3 months post-treatment com-
pared with pretreatment.
The final models also showed that there were positive associa-
tions between the following: living in a multi-dog household
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Figure 2. Continued
Antibiotics select for AMR canine faecal E. coli JAC
3311
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/12/3305/5095201 by U
niversity of Liverpool user on 23 January 2019
and 3GCR or ESBL-producing E. coli; recruitment from referral
consultations and AmpC-producing E. coli (compared with first
opinion); eating animal stools and FQR; owner working in health-
care and MDR; a ‘diagnosis of pyoderma’ and ESBL-producing
E. coli; and body weight and AmpC-producing E. coli (dogs of small
to medium weight were less likely than large dogs to have
resistance).
Discussion
This study used a prospective, longitudinal design to examine the
effect of different antimicrobials on the selection and carriage of
AMR amongst faecal E. coli in a large cohort of vet-visiting dogs.
Faecal samples were collected before treatment and at multiple
timepoints, including 3 months, after completing therapy.
Resistance to critically important antimicrobials was investigated
(including third-generation cephalosporins and fluoroquinolones).
Our findings suggest that single courses of systemic antimicrobials
select for resistance immediately after treatment, but effects then
wane. In particular, b-lactams selected for 3GCR and/or MDR, and
cephalosporins and fluoroquinolones selected for FQR. This sug-
gests that broad-spectrum antimicrobials authorized for the treat-
ment of bacterial infections in dogs create a reservoir of AMR E. coli
and potentially transmissible resistance genes within the canine
gastrointestinal tract. Both can provide a source of environmental
contamination, be transmitted to other hosts, including owners, or
influence re-infection.
Selection of 3GCR including AmpC
Treatment with cefalexin and cefovecin significantly increased the
risk of detecting 3GCR, in particular AmpC-producing E. coli. These
results confirm those of Damborg et al.,39 who examined
cefalexin-only treatment in a small number of community dogs
compared with untreated controls and also found an increase in
AmpC-producing E. coli. Similarly, Lawrence et al.20 reported
increased AmpC-producing faecal E. coli 28 days after cefovecin-
injection treatment in a small number of laboratory Beagles.
Impact of amoxicillin/clavulanate
It was surprising that amoxicillin/clavulanate (aminopenicillin plus
b-lactamase inhibitor combination), the other b-lactam antimicro-
bial investigated in this study, did not significantly select for
AmpC-producing E. coli, as did the cephalosporins. Treatment with
amoxicillin/clavulanate is expected to select for 3GCR due to Amp-
C production, but not necessarily ESBL-mediated resistance.
Clavulanate, a b-lactamase inhibitor, is less effective against
AmpC-b-lactamases, so could select for these enzymes over other
b-lactamases, including ESBL-variants.40,41 Gibson et al.16 also
reported that, unexpectedly, they did not detect treatment with
b-lactams or potentiated-b-lactams as risks for MDR AmpC-
producing E. coli in hospitalized dogs; however, the findings of
other studies support the selection of b-lactam resistance follow-
ing treatment with amoxicillin without clavulanate.15,18 Although
the amoxicillin/clavulanate treatment group was of similar size to
Table 3. Multilevel multivariable results for the outcomes: FQR and MDR in 457 faecal samples from 127 dogs
Variable(s)
FQR MDR
OR 95% CI P OR 95% CI P
Time D0 ref. – – ref. – –
Time E and cefalexin 5.1 1.6–16.6 0.006 1.7 0.6–5.0 0.4
Time E and amoxicillin/clavulanate 1.4 0.3–7.1 0.72 5.0 1.5–16.0 0.007
Time E and cefovecin 7.0 1.9–25.5 0.003 8.0 2.1–30.6 0.002
Time E and clindamycin 0.7 0.1–4.9 0.7 1.6 0.4–5.7 0.5
Time E and fluoroquinolone 5.6 1.2–25.7 0.03 0.8 0.2–4.0 0.8
Time M1 and cefalexin 2.02 0.5–8.8 0.35 2.1 0.7–7.0 0.2
Time M1 and amoxicillin/clavulanate 2.1 0.5–9.3 0.34 0.6 0.1–2.5 0.5
Time M1 and cefovecin 0.8 0.1–5.7 0.82 1.6 0.3–7.3 0.6
Time M1 and clindamycin 0.3 0.02–4.1 0.37 1.8 0.5–6.4 0.4
Time M1 and fluoroquinolone 2.7 0.3–22.9 0.34 1.8 0.2–14.1 0.6
Time M3 and cefalexin 0.4 0.03–5.6 0.53 0.7 0.2–2.8 0.6
Time M3 and amoxicillin/clavulanate 1.0 0.2–6.9 0.99 2.0 0.6–7.2 0.3
Time M3 and cefovecin 2.5 0.5–12.4 0.25 1.2 0.3–6.1 0.8
Time M3 and clindamycin 0.4 0.03–6.02 0.54 0.4 0.1–1.8 0.2
Time M3 and fluoroquinolone 2.9 0.4–23.0 0.32 0.3 0.02–4.5 0.4
Time treatment overall – – 0.09 – – 0.045
Owner works in healthcare – – – 3.6 1.32–9.88 0.012
Dog eats animal stools 2.9 1.2–7.0 0.018 – – –
Level 2 (dog) variance (standard error) VPC 1.6 (0.6) 32% – – 2.7 (0.7) 45% – –
D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; VPC, variance partition coefficient.
P values are from the Wald v2 test; significant if P,0.05 (bold text).
Schmidt et al.
3312
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/12/3305/5095201 by U
niversity of Liverpool user on 23 January 2019
other treatment groups, apart from the fluoroquinolones, we can-
not exclude a sample-size effect and larger studies are required to
investigate these findings further; other factors, such as differing
antimicrobial excretion and concentration within the intestinal
tract, should be investigated.
Selection for ESBL, MDR and FQR
The detection of ESBL-producing E. coli was not associated with
use of any antimicrobials administered in this study, as previously
reported.14,42,43 The percentage of samples positive for ESBL-
producing E. coli was lower overall than other resistance out-
comes. This may have reduced the power to detect significant
associations, particularly as cefalexin and cefovecin were found to
be a risk for 3GCR, an outcome including phenotypic ESBL- and
AmpC-producing E. coli. Furthermore, previous studies in both
healthy and hospitalized dogs23,24,44 have reported a higher preva-
lence of canine faecal AmpC-producing compared with ESBL-
producing E. coli.
In this study, the administration of both amoxicillin/clavulanate
and cefovecin increased the risk of detecting MDR E. coli
post-treatment. These results uphold previous work using
a small number of dogs, where selection for MDR faecal
E. coli followed treatment with ampicillin, amoxicillin, enrofloxacin
or cefovecin;15,18,20,45 retrospective risk analysis also identified
cefalexin as a risk for MDR E. coli rectal carriage during hospitaliza-
tion.16 Cefovecin was also a risk for the detection of AmpC-
producing E. coli, which are often MDR.40
The use of cephalosporins and fluoroquinolone antimicrobials
increased the risk of detecting FQR post-treatment in this study.
This upholds results from Boothe and Debavalya18 (selection of
MDR FQR E. coli following treatment with enrofloxacin in two la-
boratory dogs) and Lawrence et al.20 (increased detection of
enrofloxacin-resistant faecal E. coli after administration of cefovecin).
As E. coli strains with high-level FQR are commonly resistant to
cephalosporins,46 this suggests co-selection of resistance.2
However, we did not find an association between fluoroquinolone
therapy and MDR or 3GCR at treatment end, possibly due to a
small sample size in this treatment group.
Table 4. Multilevel multivariable results for 3GCR and phenotypic ESBL- or AmpC-producing E. coli in 457 faecal samples from 127 dogs
Variable(s)
3GCR ESBL AmpC
OR 95% CI P OR 95% CI P OR 95% CI P
Time D0 ref. – – ref. – – ref. – –
Time E and cefalexin 8.7 2.9–25.9 ,0.001 1.6 0.5–4.8 0.42 8.84 3.1–25.4 ,0.001
Time E and amoxicillin/clavulanate 3.9 1.1–14.5 0.04 1.3 0.2–7.6 0.77 2.81 1.0–8.3 0.06
Time E and cefovecin 9.6 2.5–37.7 0.001 2.5 0.8–8.3 0.12 9.31 2.7–31.9 ,0.001
Time E and clindamycin 1.0 0.3–3.8 0.99 0.4 0.1–3.5 0.43 0.78 0.2–2.7 0.69
Time E and fluoroquinolone 0.6 0.1–3.2 0.51 2.4 0.5–11.5 0.29 0.47 0.1–2.6 0.39
Time M1 and cefalexin 2.2 0.7–6.9 0.182 0.5 0.1–2.5 0.41 2.76 1.0–8.0 0.06
Time M1 and amoxicillin/clavulanate 5.3 1.5–19.7 0.013 3.0 0.7–13.1 0.14 1.59 0.5–4.9 0.42
Time M1 and cefovecin 1.3 0.3–5.2 0.71 2.1 0.6–7.7 0.28 1.85 0.6–6.1 0.31
Time M1 and clindamycin 0.7 0.2–3.1 0.63 0.6 0.1–4.6 0.59 1.04 0.3–3.7 0.96
Time M1 and fluoroquinolone 0.7 0.1–5.3 0.69 0.9 0.1–10.4 0.91 0.42 0.03–5.8 0.52
Time M3 and cefalexin 0.8 0.2–2.6 0.57 0.9 0.2–3.8 0.91 0.62 0.2–2.3 0.47
Time M3 and amoxicillin/clavulanate 1.6 0.4–6.3 0.54 0.7 0.1–6.5 0.73 0.42 0.1–1.7 0.23
Time M3 and cefovecin 2.9 0.7–11.8 0.14 0.8 0.1–4.4 0.76 1.83 0.5–6.2 0.33
Time M3 and clindamycin 0.5 0.1–2.8 0.44 0.7 0.1–5.2 0.69 0.28 0.04–1.9 0.19
Time M3 and fluoroquinolone 0.8 0.1–6.6 0.87 1.1 0.1–11.2 0.92 0.96 0.1–7.2 0.97
Time treatment overall – – ,0.001 – – 0.77 – – ,0.001
Weight (large) ref. – – ref. – – ref. – –
Weight (small) – – – – – – 0.5 0.2–1.4 0.17
Weight (medium) – – – – – – 0.1 0.03–0.5 0.004
Weight overall – – – – – – – – 0.009
Diagnosis of pyoderma 2.3 0.8–6.6 0.11 3.63 1.18–11.13 0.024 – – –
First opinion RE – – ref. – – ref. – –
Referral consultation 2.1 0.9–5.2 0.11 – – – 2.2 1.1–4.6 0.035
Multi-dog household 3.8 1.6–8.7 0.002 2.71 1.24–5.93 0.012 – – –
Level 2 (dog) variance (standard error) VPC 2.4 (0.6)
43%
– – 1.190 (0.5)
27%
– – 1.8 (0.5)
35%
– –
D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; VPC, variance partition coefficient; ref., reference
category.
P values are from the Wald v2 test; significant if P,0.05 (bold text).
Antibiotics select for AMR canine faecal E. coli JAC
3313
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/12/3305/5095201 by U
niversity of Liverpool user on 23 January 2019
Antimicrobial exposure recovery period
Chronic antimicrobial therapy likely maintains MDR amongst ca-
nine commensal E. coli.47 Our study aimed to report AMR preva-
lence and risk factors at timepoints post-treatment, but in the
absence of repeated antimicrobial prescriptions. We found that
after amoxicillin/clavulanate treatment the risk of detecting 3GCR
E. coli increased and remained higher at 1 month post-treatment,
but at 3 months it had returned to pretreatment levels. The length
of time for which significantly different levels of resistance were
evident is longer than that suggested in previous work examining
amoxicillin without clavulanate; Gronvold et al.15 and Boothe and
Debavalya18 showed recovery at 2 weeks post-treatment. This
may mean that whilst amoxicillin/clavulanate may have less over-
all impact on the selection for 3GCR than cephalosporins, the treat-
ment effects are longer lasting. Further larger studies are required
to corroborate and investigate the basis of these findings. For ex-
ample, amoxicillin/clavulanate may have differing effects on other
members of the microbiome (such as anaerobic bacteria) com-
pared with cephalosporins, where higher-generation drugs have
increasing activity against Gram-negative bacteria. For other treat-
ment groups (cefalexin, cefovecin, clindamycin and fluoroquino-
lones) there was no association with resistance at 1 month post-
treatment. Previous work, however, identified resistance at
21 days and between 17 and 37 days after enrofloxacin (Boothe
and Debavalya18 and Trott et al.,13 respectively) and resistance at
day 28 after cefovecin.20
Length of antimicrobial treatment
The length of antimicrobial treatment has been investigated par-
ticularly for human patients and shorter courses have been shown
to reduce antimicrobial use, costs, adverse events and exposure to
commensal organisms (and thereby AMR selection), without
increasing morbidity or mortality.48 The results of this study, how-
ever, did not suggest an association between treatment length
and resistance, particularly given the shorter treatment length for
amoxicillin/clavulanate; however, sample sizes were small in
some groups, reducing the likelihood of detecting associations be-
tween variables. Overall, selection and persistence of resistance
within the gastrointestinal tract is likely to be influenced by mul-
tiple factors, including antimicrobial class (broad or narrow spec-
trum), resistance type (MDR or not) and mechanism of resistance
(transmissible or chromosomal),18 pharmacokinetics/pharmaco-
dynamics, the level of resistance present before therapy7 and bac-
terial virulence/fitness.49
Magnitude of resistance
Quantifying resistance (assessing the number of isolates with an
AMR trait) would be a better measure to detect changes over time
than analysis at the sample level (sample classed as AMR if at least
one isolate is AMR), particularly where there is high pretreatment
AMR prevalence. High pretreatment prevalence can make it diffi-
cult to detect change following therapy, increase the risk of AMR in
the following sample and influence recovery time. This study limi-
tation was offset by selecting 10 random isolates from non-
selective agar for each sample for analysis at the isolate level for
each timepoint/treatment group. At the sample level, this
study did not identify an association between cefalexin or
fluoroquinolone therapy with MDR E. coli; however, there was an
increase immediately at treatment end compared with pretreat-
ment when examined at the isolate level; this concurs with our
expectations and the findings of previous authors.13,18,20,45
Concordantly, also at the isolate level, fluoroquinolone and cefove-
cin therapy appeared to have the most effect on fully susceptible
E. coli; this was also noted at the sample level, where E. coli were
not detected in over one-third of dogs directly after fluoroquino-
lone treatment. Both Lawrence et al.20 and Trott et al.13 reported
significant inhibition of faecal E. coli and/or coliforms during and
beyond treatment with cefovecin and enrofloxacin. Inhibition of
susceptible isolates may create a vacant niche in the gastrointes-
tinal tract for colonization with resistant or pathogenic bacteria.
Study implications
Antimicrobial therapy selects for MDR E. coliwithin the gastrointes-
tinal tract of humans and dogs. These bacteria may be then shared
between hosts (including between humans or between pets and
between humans and pets) within households4,5 and healthcare
settings; carriage isolates may cause extra-intestinal infec-
tions.16,50 Antimicrobial therapy is paramount to the successful
treatment of many patients. Implementation of veterinary hos-
pital prescribing guidelines can reduce overall use and misuse of
important antimicrobials,51 reducing selection pressure for AMR
bacteria. This study provides important information on both the ef-
fect and the timescale of the effect following routine antimicrobial
therapy in dogs. This information can be used to design biosecurity
guidelines that limit transfer of such bacteria to in-contact individ-
uals or to the environment, including barrier nursing,52,53 appropri-
ate disposal of dog waste6 and strict hand hygiene.54,55
Conclusions
Antimicrobials impact not just the pathogens they are designed to
target, but also the commensal microbiota. Our results suggest
that treatment with many commonly used systemic antimicro-
bials (particularly b-lactams and fluoroquinolones) affects the
commensal faecal flora of dogs, causing a shift towards a more re-
sistant bacterial population of E. coli. There is a window of up to
1 month following the end of therapy when treated dogs are more
likely to carry AMR faecal E. coli. Proactive strategies such as pru-
dent antimicrobial prescribing and hospital biosecurity pro-
grammes are urgently needed to limit development and
dissemination of AMR. In particular, policies for antimicrobial use
during specific clinical conditions, alongside utilization of culture
and susceptibility testing, could help reduce misuse and overuse of
important antimicrobials. Full genome sequencing, e.g. deep
sequencing of shotgun metagenomics of the microbiome, could
help to elucidate the overall impact of therapy with different
antimicrobials.
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